Bristol-Myers Squibb Company (NYSE:BMY) finished Wednesday with a subtraction of -$0.3 to close at $61.56, a downside of -0.48 percent. An average of 10,512,240 shares of common stock have been traded in the last five days. There was a gain of $0.63 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 12,417,445 shares traded, while the 50-day average volume stands at 10,084,378.
BMY stock has decreased by -3.47% in the last month. The company shares reached their 1-month lowest point of $59.71 on 08/08/23. With the stock rallying to its 52-week high on 02/06/23, shares of the company touched a low of $59.71 and a high of $81.43 in 52 weeks. It has reached a new high 9 times so far this year and lost -14.44% or -$10.39 in price. In spite of this, the price is down -24.41% from the 52-week high.
Insider Transactions
BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 21 days ago on Aug 03. In this transaction, the insider spent $44,754. EVP & President, Research, VESSEY RUPERT, disposed of 50,385 shares at a price of $67.06 on May 03. The insider now owns more than $3,378,818 worth of shares. Prior to that, Board Chair and CEO Caforio Giovanni went on to Sale 240,000 shares at $74.65 each on Feb 06. An amount of $17,916,000 was transacted.
Valuation Metrics
Bristol-Myers Squibb Company (BMY) has a trailing price-to-earnings (P/E) ratio of 16.39. The stock’s beta is 0.40. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.85, the price-to-book (PB) ratio at 4.03, and the price-to-cash flow ratio at 12.01.
The company has a payout ratio of 58.70%. The company’s most recent quarterly dividend payment was $0.57 a share, without any change from last year. Its latest increase dividend $0.03 reported on Thursday December 8 2022.
Financial Health
The quick ratio of Bristol-Myers Squibb Company for the three months ended June 29 was 1.30, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.08 and a total debt to equity ratio of 1.18 for the quarter ending June 29. Bristol-Myers Squibb Company’s EBITDA margin for the year ending June 29 is 42.37%, while its operating margin for the same period stands at 22.00%. Its gross profit as reported stood at $36.02 billion compared to revenue of $46.16 billion.
Earnings Surprise
For the three-month period that ended June 29, Bristol-Myers Squibb Company had $34.66 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $2.07 billion in the quarter, while revenues of $2.26 billion were grew 31.45%. The analyst consensus anticipated Bristol-Myers Squibb Company’s latest quarter earnings to come in at $1.98 per share, but it turned out to be $1.75, a -11.60% surprise. For the quarter, EBITDA amounted to $4.29 billion. Shareholders own equity worth $2.09 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Bristol-Myers Squibb Company (BMY) price momentum. RSI 9-day as of the close on 23 August was 47.97%, suggesting the stock is Neutral, with historical volatility in this time frame at 13.46%.
As of today, BMY’s price is $61.91 +1.03% or $0.63 from its 5-day moving average. BMY is currently trading -2.92% lower than its 20-day SMA and -9.74% lower than its 100-day SMA. However, the stock’s current price level is -4.94% below the SMA50 and -21.56% below the SMA200.
The stochastic %K and %D were 68.77% and 73.54%, respectively, and the average true range (ATR) was 0.97. With the 14-day stochastic at 61.56% and the average true range at 1.02, the RSI (14) stands at 46.50%. The stock has reached 0.10 on the 9-day MACD Oscillator while the 14-day reading was at 0.48.
Analyst Ratings
HSBC Securities launched coverage on Bristol-Myers Squibb Company (NYSE: BMY) in its analyst report released on July 14, 2023. The firm assigned the stock a Reduce rating. The consensus rating for Bristol-Myers Squibb Company (BMY) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell BMY, while 11 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 12 others rate it as a “buy”.
What is BMY’s price target for the next 12 months?
Analysts predict a range of price targets between $56.00 and $90.00, with a median target of $74.50. Taking a look at these predictions, the average price target given by analysts for Bristol-Myers Squibb Company (BMY) stock is $73.36.
